GLP-1R (human):Fc (silent) InVivoKine(tm)

AdipoGen Life Sciences

GLP-1R (human):Fc (silent) InVivoKine(tm)

10

Research Use Only

1 mg/ml

>95%

Glucagon-like peptide 1 (GLP-1) is a 30-amino acid Incretin peptide hormone produced in the intestine by differential processing of proglucagon. Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate insulin secretion together with hyperglycemia. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are the known incretin hormones from the upper (GIP, K cells) and lower (GLP-1, L cells) gut. GLP-1 receptors are abundant in the hypothalamus which contains projections to the hunger centers. GLP-1 decreases calorie intake, boosts feelings of satiety and encourages weight loss. GLP-1 and GIP hormones are used as drugs for weight loss in obese patients and also to lower blood sugar levels. The GLP-1R (human) (monomer):Fc (silent) InVivoKine™ is produced by using two different vectors, one encoding for the GLP-1R (human:Fc (LALA-PG) Knobs sequence (synthesizing a protein of 60kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein GLP-1R (human) (monomer):Fc (silent) InVivoKine™. The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences. - InVivoKines™. Recombinant Protein. Extracellular domain of human GLP-1R (aa 24-139) is fused at the C-terminus to the Fc portion of human IgG1 (LALA-PG) (Knobs-into-Holes technology) (see reference: J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)). Source: HEK 293 cells. Produced using animal component-free medium. Lyophilized. Contains PBS. Glucagon-like peptide 1 (GLP-1) is a 30-amino acid Incretin peptide hormone produced in the intestine by differential processing of proglucagon. Incretin hormones are gut peptides that are secreted after nutrient intake and stimulate insulin secretion together with hyperglycemia. GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are the known incretin hormones from the upper (GIP, K cells) and lower (GLP-1, L cells) gut. GLP-1 receptors are abundant in the hypothalamus which contains projections to the hunger centers. GLP-1 decreases calorie intake, boosts feelings of satiety and encourages weight loss. GLP-1 and GIP hormones are used as drugs for weight loss in obese patients and also to lower blood sugar levels. The protein GLP-1R (human):Fc (LALA-PG)-KIH (human) (rec.) is produced by using two different vectors, one encoding for the GLP-1R (human:Fc (LALA-PG) Knobs sequence (synthesizing a protein of 60kDa) and one encoding for the Fc (LALA-PG) Holes sequence (synthesizing a protein of 28kDa). Both vectors transfected into HEK293 cells produce both Fc molecules (Knobs-into-Holes technology; J.B. Ridgway, et al.; Protein Eng. 9, 617 (1996)) required for dimerization of the Fc moieties and for secretion of the final protein GLP-1R (human):Fc-KIH (human) (rec.). The LALA-PG mutations inhibit binding to FcgammaRs and C1q while FcRn binding and Fc stability remain unaffected. InVivoKines™ are a new generation of recombinant fusion proteins for immunotherapeutic, preclinical and translational in vivo research, developed and manufactured by AdipoGen Life Sciences.

-20°C,2°C to 8°C

41116100